Zobrazeno 1 - 10
of 64
pro vyhledávání: '"A. Z., Alanazi"'
Autor:
Lobna Aljuffali, Amjad Faihan BinLebdah, Rihaf Alfaraj, Dalal Alkhelb, Jawza F. Alsabhan, Ahmed Z. Alanazi, Khalid Alhazzani
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 9, Pp 102151- (2024)
This study explores the course review process implemented by the College of Pharmacy at King Saud University for its Pharm.D. program. Through a qualitative research design, a dedicated course review committee was established to oversee the evaluatio
Externí odkaz:
https://doaj.org/article/2729296f01e948119a4d1905f29508f9
Autor:
Alanzi, Abdullah R.1 (AUTHOR) aralonazi@ksu.edu.sa, A. Z., Alanazi2 (AUTHOR), Alhazzani, Khalid2 (AUTHOR)
Publikováno v:
PLoS ONE. 8/22/2024, Vol. 19 Issue 8, p1-23. 23p.
Autor:
Ashokkumar Thirunavukkarasu, Abdulrahman Raji Alanazi, Abdullah N. Al-Rasheedi, Danah Khalid Alruwaili, Doaa Mazen Abdel-Salam, Nasser Saleh Alriwely, Abdulrahman Fayez J. Alruwaili, Abdulhadi Abdullah Z. Alanazi, Sultan Farhan O. Alruwaili, Abdulaziz Raja R. Alruwaili
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
Background and aimChildhood choking is a global health concern that mainly affects children under the age of 5 years. The parent’s and caretaker’s responsibility is critical in the children’s lives and can potentially influence the result of at
Externí odkaz:
https://doaj.org/article/cfb7ac9e01214f92955d4c2e5ef7f121
Autor:
Hussain N. Alhamami, Abdullah M. Albogami, Mohammad M. Algahtani, Mohammed Alqinyah, Wael A. Alanazi, Fawaz Alasmari, Khalid Alhazzani, Ahmed Z. Alanazi, Yasseen A. Alassmrry, Abdullah S. Alhamed
Publikováno v:
Saudi Pharmaceutical Journal, Vol 32, Iss 3, Pp 101964- (2024)
Autism spectrum disorder (ASD) is a complex neurodevelopmental illness that often emerges in early childhood. The incidence of ASD has shown a notable rise in recent years. ASD is defined by deficits in social communication, and presence of rigid and
Externí odkaz:
https://doaj.org/article/ee4d6babcffd49a5aa4beaed78b8488d
Autor:
Khalid Alhazzani, Meshal Alsahli, Ahmed Z Alanazi, Mohammad Algahtani, Ahmad A Alenezi, Ali Alhoshani, Mohammed Alqinyah, Abdullah S. Alhamed, Khaled Alhosaini
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 10, Pp 101756- (2023)
Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) in
Externí odkaz:
https://doaj.org/article/783dc35bd01445c093370055e31360d3
Autor:
Ahmed Z. Alanazi, Salim S. Al-Rejaie, Mohammed M. Ahmed, Khalid Alhazzani, Khaled Alhosaini, Homood M. As Sobeai, Sary Alsanea, Perwez Alam, Omer M. Almarfadi, Ali S. Alqahtani, Abdullah S. Alhamed, Mohammed Alqinyah, Hussain N. Alhamami, Mohammed F. Almutery, Mohamed Mohany
Publikováno v:
Saudi Pharmaceutical Journal, Vol 31, Iss 8, Pp 101669- (2023)
Previous investigations have shown that D. viscosa herbal extract is often used to treat a variety of diseases. Therefore, the purpose of this study was to investigate any additional potential impacts on rat liver and kidney damage induced by diabete
Externí odkaz:
https://doaj.org/article/602507ebe5c640fbb50a64087a4c681e
Autor:
Wael A. Alanazi, Hussain N. Alhamami, Metab Alharbi, Khalid Alhazzani, Abdulrahman S. Alanazi, Sary Alsanea, Nemat Ali, Abdullah F. Alasmari, Ahmed Z. Alanazi, Moureq R. Alotaibi, Mohammed Alswayyed
Publikováno v:
Saudi Pharmaceutical Journal, Vol 30, Iss 8, Pp 1159-1169 (2022)
Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), used for the treatment of advanced or metastatic non-small cell lung cancer. Recently, studies proved that Gefitinib-induced cardiotoxicity through inducti
Externí odkaz:
https://doaj.org/article/ffd8774970444e2db83a36fd880b8ec0
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp S84- (2023)
Intro: During the pandemic of COVD-19, several vaccines have been developed and are currently used worldwide. However, head-to-head studies comparing various vaccines are limited. Therefore, This single-center, prospective, realworld study. head-to-h
Externí odkaz:
https://doaj.org/article/f798687bf84543fc8c3c804a1f262abf
Autor:
Khalid Alhazzani, Abdullah Almangour, Abdulaziz Alsalem, Mohammed Alqinyah, Abdullah S. Alhamed, Hussain N. Alhamami, Ahmed Z. Alanazi
Publikováno v:
Diseases, Vol 11, Iss 4, p 147 (2023)
Background: Dasatinib, nilotinib, and sorafenib are clinically proven tyrosine kinase inhibitors (TKIs) used for the treatment of leukemia and hepatocellular carcinoma. However, there is a growing concern regarding cardiotoxicity associated with thei
Externí odkaz:
https://doaj.org/article/d71b5d579a6f42498ea9287f14db0cd9
Autor:
Ahmed Z. Alanazi, Khalid Alhazzani, Salah Q. Alrewily, Khaldoon Aljerian, Mohammad M. Algahtani, Qamraa H. Alqahtani, Dhanush Haspula, Abdullah S. Alhamed, Mohammed Alqinyah, Mohammad Raish
Publikováno v:
Pharmaceuticals, Vol 16, Iss 7, p 921 (2023)
Dasatinib (DASA) is a novel tyrosine kinase inhibitor, approved for leukemia treatment. However, the long-term use of DASA induces several complications, especially liver damage. On the other hand, Naringenin (NGN) is a potent antioxidant and anti-in
Externí odkaz:
https://doaj.org/article/671e7d1387084c2bbfeb0d8b8993df42